MARKET

VTGN

VTGN

VistaGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7000
+0.1300
+22.81%
After Hours: 0.7000 0 0.00% 17:25 12/13 EST
OPEN
0.5900
PREV CLOSE
0.5700
HIGH
0.7300
LOW
0.5660
VOLUME
1.59M
TURNOVER
--
52 WEEK HIGH
1.860
52 WEEK LOW
0.2943
MARKET CAP
30.26M
P/E (TTM)
-0.9974
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VTGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VTGN News

  • VistaGen Granted FDA Fast Track Designation For PH94B For Treatment Of Social Anxiety Disorder
  • Benzinga.3d ago
  • U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
  • PR Newswire.3d ago
  • Sage Therapeutics' Depression Drug Fails in Study, Stock Down
  • Zacks.12/06 14:26
  • Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
  • Zacks.11/20 14:31

More

Industry

Pharmaceuticals
+0.14%
Pharmaceuticals & Medical Research
-0.08%

Hot Stocks

Name
Price
%Change

About VTGN

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
More

Webull offers Vistagen Therapeutics Inc (VTGN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.